Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug;9(3):e003281.
doi: 10.1136/rmdopen-2023-003281.

Invasive fungal diseases in patients with autoimmune diseases: a case series from the French RESSIF network

Collaborators, Affiliations

Invasive fungal diseases in patients with autoimmune diseases: a case series from the French RESSIF network

Simon Galmiche et al. RMD Open. 2023 Aug.

Abstract

Objectives: We aimed to describe patients with autoimmune diseases (AID) developing invasive fungal disease (IFD) and identify factors associated with short-term mortality.

Methods: We analysed cases of IFD associated with AID from the surveillance network of invasive fungal diseases (Réseau de surveillance des infections fongiques invasives, RESSIF) registry of the French national reference centre for invasive mycoses. We studied association of AID-specific treatments with 30-day mortality. We analysed total lymphocyte and CD4-T cell counts in patients with Pneumocystis jirovecii pneumonia (PCP).

Results: From 2012 to 2018, 549 individuals with IFD and AID were included, mainly with PCP (n=227, 41.3%), fungemia (n=167, 30.4%) and invasive aspergillosis (n=84, 15.5%). Rheumatoid arthritis (RA) and anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitides (AAV) were the most frequent AID in PCP (n=55 and 25, respectively) and invasive aspergillosis (n=15 and 10, respectively), inflammatory bowel diseases (IBDs) were predominant in fungemia (n=36). At IFD diagnosis, 365 (66.5%) patients received glucocorticoids (GCs), 285 (51.9%) immunosuppressants, 42 (7.7%) tumor necrosis factor (TNF)-α blockers, 75 (13.7%) other biologics. Mortality at 30 days was 28.1% (143/508). Fungemia and high-dose GCs were independently associated with higher 30-day mortality. In PCP patients, lymphopenia <1500/mm3 was frequent (132/179, 73.7%) even if CD4+T cell count exceeded 200/mm3 in 56/78 patients (71.8%) (median 472.5/mm3, IQR 160-858).

Conclusion: IFD associated with AID occurs primarily in RA, AAV and IBD, especially when treated with GCs and immunosuppressants. Mortality is high, especially for patients on high-dose GCs. Lymphopenia may help identify risk of PCP, but normal CD4+T cell count does not rule out the risk. Further studies are needed to assess the individual risk factors for IFD.

Keywords: Antirheumatic Agents; Arthritis, Rheumatoid; Autoimmune Diseases; Glucocorticoids.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Forest plot of factors associated with 30-day mortality following diagnosis of invasive fungal disease (IFD) in patients with autoimmune diseases (AID) (France, 2012–2018). ORs in a fitted multivariable logistic regression model. Beyond variables presented in the figure, the model also includes age (in years), sex, underlying comorbidities (solid cancer, haematological malignancy, solid organ transplantation, cirrhosis, chronic kidney failure, chronic respiratory failure), co-occurring bacterial of viral infection. High-dose glucocorticoids: over 0.3 mg/kg/day for over 1 month. Further results of the model, as well as the univariable effects, are presented in online supplemental table S14. Results in a population restricted to the 322 without any other major risk factor for IFD (solid cancer, haematological malignancy, solid organ transplantation, recent surgery) are also reported in online supplemental table S14.

References

    1. Liu Y, Su L, Jiang S-J, et al. . Risk factors for mortality from Pneumocystis carinii pneumonia (PCP) in non-HIV patients: a meta-analysis. Oncotarget 2017;8:59729–39. 10.18632/oncotarget.19927 - DOI - PMC - PubMed
    1. Godeau B, Coutant-Perronne V, Le Thi Huong D, et al. . Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol 1994;21:246–51. - PubMed
    1. Roux A, Canet E, Valade S, et al. . Pneumocystis Jirovecii pneumonia in patients with or without AIDS, France. Emerg Infect Dis 2014;20:1490–7. 10.3201/eid2009.131668 - DOI - PMC - PubMed
    1. Ward MM, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum 1999;42:780–9. 10.1002/1529-0131(199904)42:4<780::AID-ANR23>3.0.CO;2-M - DOI - PubMed
    1. Bruce ES, Kearsley-Fleet L, Watson KD, et al. . Risk of Pneumocystis Jirovecii pneumonia in patients with rheumatoid arthritis treated with inhibitors of tumour necrosis factor Α: results from the British society for rheumatology Biologics register for rheumatoid arthritis. Rheumatology (Oxford) 2016;55:1336–7. 10.1093/rheumatology/kew200 - DOI - PubMed

Publication types